Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(7), P. e2325332 - e2325332

Published: July 25, 2023

Importance Liquid biopsy has emerged as a complement to tumor tissue profiling for advanced non–small cell lung cancer (NSCLC). The optimal way integrate liquid into the diagnostic algorithm patients with newly diagnosed NSCLC remains unclear. Objective To evaluate use of circulating DNA (ctDNA) genotyping before diagnosis among suspected and its association time treatment. Design, Setting, Participants This single-group nonrandomized clinical trial was conducted 150 at Princess Margaret Cancer Centre–University Health Network (Toronto, Ontario, Canada) between July 1, 2021, November 30, 2022. Patients referred investigation were eligible if they had radiologic evidence prior diagnosis. Interventions underwent plasma ctDNA testing next-generation sequencing (NGS) assay Diagnostic NGS performed per standard care. Main Outcome Measures primary end point from referral treatment initiation nonsquamous using (ACCELERATE [Accelerating Lung Diagnosis Through Biopsy] cohort). cohort compared reference after Results Of (median age diagnosis, 68 years [range, 33-91 years]; 80 men [53%]) enrolled, 90 (60%) NSCLC. median 39 days (IQR, 27-52 days) ACCELERATE vs 62 44-82 ( P < .001). Among cohort, turnaround sample collection results 7 6-9 23 18-28 NSCLC, 21 (23%) started targeted therapy available, 11 (12%) actionable alterations identified only through testing. Conclusions Relevance found that associated accelerated undergoing Trial Registration ClinicalTrials.gov Identifier: NCT04863924

Language: Английский

---

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

Journal of Molecular Diagnostics, Journal Year: 2023, Volume and Issue: 26(1), P. 73 - 84

Published: Nov. 18, 2023

Language: Английский

---

“Plasma-first” approach for molecular genotyping in non-small cell lung cancer: A narrative review

The Journal of Liquid Biopsy, Journal Year: 2023, Volume and Issue: 2, P. 100123 - 100123

Published: Oct. 27, 2023

Molecular genotyping is essential for management of patients newly diagnosed with advanced non-small cell lung cancer (NSCLC). Plasma circulating tumor DNA (ctDNA) testing has emerged as a complement to tissue NSCLC, especially when or time are limited. The optimal way integrate ctDNA into the diagnostic algorithm NSCLC remains unclear. A "plasma-first" approach, using suspected confirmed before genotyping, may shorten treatment and yield higher rate detection actionable genomic alterations. In this review, we discuss current evidence exploring approach.

Language: Английский

---

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients with Advanced, Treatment-Naïve, Non-Small-Cell Lung Cancer

JTO Clinical and Research Reports, Journal Year: 2024, Volume and Issue: 6(3), P. 100778 - 100778

Published: Dec. 16, 2024

Language: Английский

---